Literature DB >> 15509549

Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence.

Karen Hoppens Gylys1, Jeffrey A Fein, Fusheng Yang, Dorothy J Wiley, Carol A Miller, Gregory M Cole.   

Abstract

In an effort to examine changes that precede synapse loss, we have measured amyloid-beta and a series of damage markers in the synaptic compartment of Alzheimer's disease (AD) cases. Because localization of events to the terminal region in neurons is problematic with conventional methods, we prepared synaptosomes from samples of cryopreserved human association cortex, and immunolabeled terminals with a procedure for intracellular antigens. Fluorescence was quantified using flow cytometry. The viability dye calcein AM was unchanged in AD terminals compared to controls, and the fraction of large synaptosome particles did not change, although a striking loss of large terminals was observed in some AD cases. The percent positive fraction for a series of pre- and postsynaptic markers was not affected by AD in this cohort. However, the amyloid-beta-positive fraction increased from 16 to 27% (P < 0.02) in terminals from AD cortex. The expression level on a per-terminal basis is indicated in this assay by fluorescence (relative fluorescence units). The fluorescence of presynaptic markers did not change in AD terminals, but PSD-95 fluorescence was decreased by 19% (P < 0.03). Amyloid-beta fluorescence was increased by 132% (P < 0.01), and glial fibrillary acidic protein labeling by 31% (P < 0.01). These results suggest that synapse-associated amyloid-beta is prominent in regions relatively unaffected by AD lesions, and that amyloid accumulation in surviving terminals is accompanied by gliosis and alteration in the postsynaptic structure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509549      PMCID: PMC1618663          DOI: 10.1016/s0002-9440(10)63436-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  58 in total

Review 1.  New roles for astrocytes: regulation of CNS synaptogenesis.

Authors:  Michal Slezak; Frank W Pfrieger
Journal:  Trends Neurosci       Date:  2003-10       Impact factor: 13.837

2.  Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.

Authors:  Rena Li; Kristina Lindholm; Li-Bang Yang; Xu Yue; Martin Citron; Riqiang Yan; Thomas Beach; Lucia Sue; Marwan Sabbagh; Huaibin Cai; Philip Wong; Donald Price; Yong Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

3.  A rapid method for preparing synaptosomes: comparison, with alternative procedures.

Authors:  P R Dodd; J A Hardy; A E Oakley; J A Edwardson; E K Perry; J P Delaunoy
Journal:  Brain Res       Date:  1981-12-07       Impact factor: 3.252

4.  Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Takeshi Kawarabayashi; Mikio Shoji; Linda H Younkin; Lin Wen-Lang; Dennis W Dickson; Tetsuro Murakami; Etsuro Matsubara; Koji Abe; Karen Hsiao Ashe; Steven G Younkin
Journal:  J Neurosci       Date:  2004-04-14       Impact factor: 6.167

5.  Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice.

Authors:  Chad A Dickey; Jeanne F Loring; Julia Montgomery; Marcia N Gordon; P Scott Eastman; Dave Morgan
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

6.  Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model.

Authors:  Frédéric Calon; Giselle P Lim; Fusheng Yang; Takashi Morihara; Bruce Teter; Oliver Ubeda; Phillippe Rostaing; Antoine Triller; Norman Salem; Karen H Ashe; Sally A Frautschy; Greg M Cole
Journal:  Neuron       Date:  2004-09-02       Impact factor: 17.173

7.  Choline uptake and acetylcholine synthesis in synaptosomes: investigations using two different labeled variants of choline.

Authors:  M H Weiler; C B Gundersen; D J Jenden
Journal:  J Neurochem       Date:  1981-05       Impact factor: 5.372

8.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

9.  Enrichment of presynaptic and postsynaptic markers by size-based gating analysis of synaptosome preparations from rat and human cortex.

Authors:  Karen H Gylys; Jeffrey A Fein; Fusheng Yang; Gregory M Cole
Journal:  Cytometry A       Date:  2004-07       Impact factor: 4.355

10.  Beta-secretase activity increases with aging in human, monkey, and mouse brain.

Authors:  Hiroaki Fukumoto; Douglas L Rosene; Mark B Moss; Susan Raju; Bradley T Hyman; Michael C Irizarry
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

View more
  113 in total

1.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

2.  Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer's disease.

Authors:  Charles Y Shao; Suzanne S Mirra; Hameetha B R Sait; Todd C Sacktor; Einar M Sigurdsson
Journal:  Acta Neuropathol       Date:  2011-06-01       Impact factor: 17.088

3.  Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody.

Authors:  Markus Mandler; Edward Rockenstein; Kiren Ubhi; Lawrence Hansen; Anthony Adame; Sarah Michael; Douglas Galasko; Radmila Santic; Frank Mattner; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 4.  Staying connected: synapses in Alzheimer disease.

Authors:  Hyoung-Gon Lee; Paula I Moreira; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

5.  PAR-1 kinase phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila neuromuscular junction.

Authors:  Yali Zhang; Huifu Guo; Helen Kwan; Ji-Wu Wang; Jon Kosek; Bingwei Lu
Journal:  Neuron       Date:  2007-01-18       Impact factor: 17.173

6.  Hsp90 chaperone inhibitor 17-AAG attenuates Aβ-induced synaptic toxicity and memory impairment.

Authors:  Yaomin Chen; Bin Wang; Dan Liu; Jing Jing Li; Yueqiang Xue; Kazuko Sakata; Ling-qiang Zhu; Scott A Heldt; Huaxi Xu; Francesca-Fang Liao
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

7.  Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease.

Authors:  Natalia Louneva; Julia W Cohen; Li-Ying Han; Konrad Talbot; Robert S Wilson; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

8.  Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease.

Authors:  Rukhsana Sultana; William A Banks; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2010-02-15       Impact factor: 4.164

Review 9.  Glial cell dysregulation: a new perspective on Alzheimer disease.

Authors:  Rommy von Bernhardi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

Review 10.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.